These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10081291)

  • 1. [12 basic rules in drug therapy of tumor pain].
    Weber M; Jage J
    Med Klin (Munich); 1999 Jan; 94(1):51-4. PubMed ID: 10081291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
    J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
    Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
    Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
    Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
    Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation.
    Klepstad P; Kaasa S; Skauge M; Borchgrevink PC
    Acta Anaesthesiol Scand; 2000 Jul; 44(6):656-64. PubMed ID: 10903012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to pain relief after immediate-release morphine in episodic pain: the TIME study.
    Lo Presti C; Roscetti A; Muriess D; Mammucari M
    Clin Drug Investig; 2010; 30 Suppl 2():49-55. PubMed ID: 20670049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.
    Geppetti P; Benemei S
    Clin Drug Investig; 2009; 29 Suppl 1():3-16. PubMed ID: 19445550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain management of opioid-treated cancer patients in hospital settings in Denmark.
    Lundorff L; Peuckmann V; Sjøgren P
    Acta Anaesthesiol Scand; 2008 Jan; 52(1):137-42. PubMed ID: 18005379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of tumor pain].
    Wiedemann B; Funke C
    Z Arztl Fortbild Qualitatssich; 1998 Jan; 92(1):23-8. PubMed ID: 9553209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
    Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
    Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
    Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H
    Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of opioid side effects.
    Walsh TD
    J Pain Symptom Manage; 1990 Dec; 5(6):362-7. PubMed ID: 1980127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term survey of morphine in cancer pain patients.
    Schug SA; Zech D; Grond S; Jung H; Meuser T; Stobbe B
    J Pain Symptom Manage; 1992 Jul; 7(5):259-66. PubMed ID: 1624812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral oxycodone: new preparation. No better than oral morphine.
    Prescrire Int; 2003 Jun; 12(65):83-4. PubMed ID: 12825566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials.
    Warfield CA
    Cancer; 1998 Jun; 82(12):2299-306. PubMed ID: 9635520
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.